var data={"title":"Eculizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Eculizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/321456?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=eculizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Eculizumab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=eculizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Eculizumab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708724\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious meningococcal infection:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Life-threatening and fatal meningococcal infections have occurred in patients treated with eculizumab. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Eculizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the Soliris REMS, health care providers must enroll in the program. Enrollment in the Soliris REMS program and additional information are available from the manufacturer (1-888-765-4747) or solirisrems.com.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426547\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Soliris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10205364\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Soliris</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426550\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Monoclonal Antibody;</li>\n      <li>\n        Monoclonal Antibody, Complement Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426649\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (McNamara 2017). Administer eculizumab at the recommended time interval or within 2 days of the interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atypical hemolytic uremic syndrome (aHUS):</b> IV: Induction: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was &ge;600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was &ge;300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized myasthenia gravis (gMG):</b> IV: Induction: 900 mg weekly for 4 doses; Maintenance: 1,200 mg at week 5, then 1,200 mg every 2 weeks thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was &ge;600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was &ge;300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal nocturnal hemoglobinuria (PNH):</b> IV: Induction: 600 mg weekly for 4 doses; Maintenance: 900 mg at week 5; then 900 mg every 2 weeks thereafter</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13259673\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=eculizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Eculizumab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation; revaccinate according to current guidelines. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (McNamara 2017). Administer eculizumab at the recommended time interval or within 2 days of the interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atypical hemolytic uremic syndrome (aHUS):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;2 months, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 kg to &lt;10 kg: Induction: 300 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 3 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 kg to &lt;20 kg: Induction: 600 mg weekly for 1 dose; Maintenance: 300 mg at week 2, then 300 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 kg to &lt;30 kg: Induction: 600 mg weekly for 2 doses; Maintenance: 600 mg at week 3, then 600 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 kg to &lt;40 kg: Induction: 600 mg weekly for 2 doses; Maintenance: 900 mg at week 3, then 900 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;40 kg: Induction: 900 mg weekly for 4 doses; Maintenance: 1200 mg at week 5, then 1200 mg every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving plasmapheresis or plasma exchange:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was 300 mg, administer 300 mg within 60 minutes after each plasmapheresis or plasma exchange</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If most recent dose was &ge;600 mg, administer 600 mg within 60 minutes after each plasmapheresis or plasma exchange</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Supplemental dosing for patients receiving fresh frozen plasma infusion:</i> If most recent dose was &ge;300 mg, administer 300 mg within 60 minutes prior to each infusion of fresh frozen plasma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426650\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426651\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426652\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426659\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Soliris: 300 mg/30 mL (30 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426548\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874616\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl.pdf#page=28&amp;token=fE75HS+0ChXD14Bwldse8u26ReDbZHn6YwMt+04IvueUulWV+SEMuABO81PZO00OsfaHFS9vnsqb0oETFmM9SYTW0plLdwqLzBtb2IlsYB0MVRz4zdP3NPfJ7EG6o1wp&amp;TOPIC_ID=8836\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125166s417lbl.pdf#page=28</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426653\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Allow to reach room temperature prior to administration. Infuse over 35 minutes in adults and over 1 to 4 hours in pediatric patients; do not administer as an IV push or bolus. Decrease infusion rate or discontinue for infusion reactions; do not exceed a maximum 2-hour duration of infusion in adults. Monitor for at least 1 hour following completion of infusion (for signs/symptoms of infusion reaction).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Assess vaccination status prior to initiation; patients must receive meningococcal vaccine at least 2 weeks prior to treatment initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426551\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atypical hemolytic uremic syndrome:</b> Treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitation of use: Eculizumab is not indicated for the treatment of patients with Shiga toxin <i>Escherichia coli</i>-related hemolytic uremic syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Generalized myasthenia gravis:</b> Treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine (AchR) antibody positive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paroxysmal nocturnal hemoglobinuria:</b> Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45748323\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Eculizumab may be confused with elotuzumab, emicizumab-kxwh, evolocumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426631\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (adolescents and adults: 17% to 59%), tachycardia (infants and children: 40%; children: 20%), peripheral edema (adolescents and adults: 20% to 29%; adults: 8%), hypotension (adolescents and adults: 12% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (adolescents and adults: 37% to 50%; infants and children: 17%), insomnia (adolescents and adults: 10% to 24%), fatigue (adolescents and adults: 7% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (12% to 22%), pruritus (adolescents and adults: 6% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (adolescents and adults: 10% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (20% to 47%), vomiting (10% to 47%), nausea (adolescents and adults: 12% to 40%; adults: 16%), abdominal pain (8% to 33%), gastroenteritis (adolescents and adults: 5% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (adolescents and adults: 15% to 35%; infants and children: 17%), uropathy (infants and children: 17%), proteinuria (adolescents and adults: 5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (adolescents and adults: 17% to 35%), neoplasm (adolescents and adults: 6% to 30%), leukopenia (adolescents and adults: 12% to 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (adolescents and adults: 24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection (infants and children: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (adolescents and adults: 15% to 20%), back pain (adolescents and adults: 5% to 19%), arthralgia (adolescents and adults: 6% to 17%), musculoskeletal pain (adults: 15%), muscle spasm (infants and children: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease (adolescents and adults: 10% to 29%; infants and children: 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (adolescents and adults: 15% to 29%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (infants and children: 20% to 60%; adolescents and adults: 12% to 30%), nasopharyngitis (adolescents and adults: 17% to 55%; infants and children: 17%), nasal congestion (infants and children: 40%; children: 20%), upper respiratory tract infection (5% to 40%), rhinitis (infants and children: 22%), bronchitis (adolescents and adults: 10% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (infants and children: 40% to 80%; adolescents and adults: 17% to 25%; adults: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Severe hypertension (5% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: High fever (infants and children: 9%; adults: 2%), severe headache (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Viral gastroenteritis (infants and children: 9%), constipation (adults: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Chronic renal failure (adolescents and adults: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (adults: 8%), severe anemia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (2% to 3%; neutralizing: 1% [no correlation to clinical response])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection (adults: 7%), viral infection (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (adults: 7% to 8%), myalgia (adults: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory tract infection (adults: 7%), sinusitis (adults: 7%), oropharyngeal pain (infants and children: 6%), flu-like symptoms (adults: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aspergillosis, meningococcal infection, septic meningitis, systemic lupus erythematosus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426627\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Unresolved serious <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>Neisseria meningitidis</i> (unless risks of treatment delay outweigh risk of developing a meningococcal infection)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to eculizumab, murine proteins, or any component of the formulation; unresolved <i>Neisseria meningitidis</i> infection; patients not currently vaccinated against <i>Neisseria meningitidis</i> (unless receiving appropriate prophylactic antibiotic treatment until 2 weeks after vaccination)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426628\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: In addition to meningitis, the risk of other infections, especially encapsulated bacteria (eg, <i>Streptococcus pneumoniae, H. influenzae</i>) is increased with eculizumab treatment (because eculizumab blocks terminal complement activation). Aspergillus infections have occurred in immunocompromised and neutropenic patients. Children should receive vaccination for prevention of <i>S. pneumoniae, H. influenzae</i> according to current ACIP guidelines. Use with caution when administering to patients with any systemic infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Infusion reactions, including anaphylaxis or hypersensitivity, may occur; interrupt infusion for severe reaction (eg, cardiovascular instability, respiratory compromise). Continue monitoring for 1 hour after completion of infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal infection: <b>[US Boxed Warning]: Meningococcal (<i>Neisseria meningitidis</i>) infections have occurred in patients receiving eculizumab; may be fatal or life-threatening if not detected and treated promptly. Monitor closely for early signs of meningococcal infection; evaluate and treat promptly if suspected. Follow current meningococcal immunization recommendations for patients with complement deficiencies. Vaccinate with meningococcal vaccines at least 2 weeks prior to initiation of treatment (unless the risks of delaying eculizumab outweigh the risk of developing meningococcal infection);</b> revaccinate according to current guidelines, considering the eculizumab duration of therapy. If urgent treatment is necessary in an unvaccinated patient, administer meningococcal vaccine(s) as soon as possible. Meningococcal infections developed in some patients despite vaccination. Prophylactic antibiotics were administered in clinical studies until at least 2 weeks after vaccination. To reduce the risk for meningococcal disease, consider antimicrobial prophylaxis with oral antibiotics (penicillin, or macrolides if penicillin-allergic) for the duration of eculizumab therapy (McNamara 2017). Discontinue eculizumab during the treatment of serious meningococcal infections.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulation: In clinical trials, anticoagulant therapy was continued in patients who were receiving these agents (due to history of or risk for thromboembolism) prior to initiation of eculizumab. The effect of anticoagulant therapy withdrawal is unknown. Treatment with eculizumab should not alter anticoagulation management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation in aHUS: Monitor patients for at least 12 weeks after treatment discontinuation for signs/symptoms of thrombotic microangiopathy (TMA) complications. Signs/symptoms of TMA include angina, dyspnea, mental status changes, seizure, or thrombosis; occurrence of two or repeated measurement of any one of the following: Serum creatinine elevation (&ge;25% from baseline or nadir), serum LDH elevation (&ge;25% from baseline or nadir), thrombocytopenia (platelet decrease by &ge;25% compared to baseline or peak). If TMA complications occur after stopping eculizumab, consider reinitiation of treatment, plasmapheresis, plasma exchange, fresh frozen plasma infusion, and/or appropriate organ-specific measures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation in PNH: Patients with PNH who discontinue eculizumab treatment may be at increased risk for serious hemolysis; monitor closely for at least 8 weeks after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be up to date with all immunizations before initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: <b>[US Boxed Warning]: Access is restricted through a REMS program. Prescribers must be enrolled in the program; enrollment and additional information is available at 1-888-765-4747 or solirisrems.com.</b> Counsel patients on the risk of meningococcal infection; ensure patients are vaccinated and provide educational materials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299250\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220068\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8836&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meningococcal Group B Vaccine: Eculizumab may diminish the therapeutic effect of Meningococcal Group B Vaccine. Meningococcal Group B Vaccine may diminish the therapeutic effect of Eculizumab. The meningococcal vaccine may result in increased complement activation, possibly worsening the symptoms of any underlying complement-mediated diseases, such as hemolysis and anemia. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426623\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Eculizumab crosses the placenta and can be detected in cord blood. Pregnant women with PNH and their fetuses have high rates of morbidity and mortality during pregnancy and the postpartum period. Treatment of PNH with eculizumab has been shown to increase fetal survival and decrease maternal complications (Kelly 2015). Use of eculizumab for the treatment of aHUS in pregnancy has also been described (Ardissino 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll women exposed to eculizumab during pregnancy by contacting the disease specific registry websites (www.pnhregistry.com or www.ahusregistry.com) or by calling 215-616-3558 (for PNH, aHUS, or gMG).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426626\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eculizumab may be present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion of eculizumab into breast milk was not noted in breast milk samples from 10 women. In a separate case report, eculizumab was detected in the initial breast milk sample of a woman, but not subsequent samples (Kelly 2015). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426656\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, lactic dehydrogenase (LDH), serum creatinine, AST, urinalysis; early signs/symptoms of meningococcal infection; signs and symptoms of infusion reaction (during infusion and for 1 hour after infusion complete). Assess meningococcal vaccination status prior to initiation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">After discontinuation:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">aHUS: Signs/symptoms of thrombotic microangiopathy (TMA) complications (monitor for at least 12 weeks after treatment discontinuation), including angina, dyspnea, mental status changes, seizure, or thrombosis; occurrence of two or repeated measurement of any one of the following: Serum creatinine elevation (&ge;25% from baseline or nadir), serum LDH elevation (&ge;25% from baseline or nadir), thrombocytopenia (platelet decrease by &ge;25% compared to baseline or peak).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PNH: Signs and symptoms of intravascular hemolysis (monitor for at least 8 weeks after discontinuation), including anemia, fatigue, pain, dark urine, dyspnea, or thrombosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426642\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Eculizumab is a humanized monoclonal IgG antibody that binds to complement protein C5, preventing cleavage into C5a and C5b. Blocking the formation of C5b inhibits the subsequent formation of terminal complex C5b-9 or MAC. Terminal complement-mediated intravascular hemolysis is a key clinical feature of paroxysmal nocturnal hemoglobinuria (PNH); blocking the formation of membrane attack complex (MAC) results in stabilization of hemoglobin and a reduction in the need for RBC transfusions. Impairment of complement activity regulation leads to uncontrolled complement activation in atypical hemolytic uremic syndrome (aHUS).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4426644\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: PNH: Reduced hemolysis: &le;1 week</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 5 to 8 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~270 to 375 hours (during plasma exchange the half-life is reduced to 1.26 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324130\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Soliris Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg/30 mL (30 mL): $7,827.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038892\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Soliris (AU, IL, JP, KR, NZ);</li>\n      <li>Solirus (AT, BE, CH, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, IT, LU, LV, MT, NL, NO, PL, PT, RO, SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M. Eculizumab for atypical hemolytic uremic syndrome in pregnancy. <i>Obstet Gynecol</i>. 2013;122(2, pt 2):487-489. doi: 10.1097/AOG.0b013e31828e2612.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/23884270/pubmed\" target=\"_blank\" id=\"23884270\">23884270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodsky RA, &ldquo;How I Treat Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>Blood</i>, 2009, 113(26):6522-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/19372253/pubmed\" target=\"_blank\" id=\"19372253\">19372253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodsky RA, Young NS, Antonioli E, et al, &ldquo;Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>Blood</i>, 2008, 111(4):1840-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/18055865/pubmed\" target=\"_blank\" id=\"18055865\">18055865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo; <i>MMWR Recomm Rep</i>, 2005, 54(RR-7):1-21. Available at <a href=\"http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf%20\" target=\"_blank\">http://www.cdc.gov/mmwr/pdf/rr/rr5407.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo; <i>MMWR Recomm Rep</i>, 2011, 60(2):1-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/21293327/pubmed\" target=\"_blank\" id=\"21293327\">21293327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations for Use of Meningococcal Conjugate Vaccines &ndash; Advisory Committee on Immunization Practices, 2010,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2011, 60(3):72-6. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/21270745/pubmed\" target=\"_blank\" id=\"21270745\">21270745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill A, Hillmen P, Richards SJ, et al, &ldquo;Sustained Response and Long-Term Safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>Blood</i>, 2005, 106(7):2559-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/15985537/pubmed\" target=\"_blank\" id=\"15985537\">15985537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Hall C, Marsh JC, et al, &ldquo;Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>N Engl J Med</i>, 2004, 350(6):552-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/14762182/pubmed\" target=\"_blank\" id=\"14762182\">14762182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Muus P, Duhrsen U, et al, &ldquo;Effect of Complement Inhibitor Eculizumab on Thromboembolism in Patients With Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>Blood</i>, 2007, 110(12):4123-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/17702897/pubmed\" target=\"_blank\" id=\"17702897\">17702897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hillmen P, Young NS, Schubert J, et al, &ldquo;The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria,&rdquo; <i>N Engl J Med</i>, 2006, 355(12):1233-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/16990386/pubmed\" target=\"_blank\" id=\"16990386\">16990386</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly RJ, H&ouml;chsmann B, Szer J, et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>N Engl J Med</i>. 2015;373(11):1032-1039. doi: 10.1056/NEJMoa1502950.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/26352814/pubmed\" target=\"_blank\" id=\"26352814\">26352814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. <i>N Engl J Med</i>. 2013;368(23):2169-2181.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/23738544/pubmed\" target=\"_blank\" id=\"23738544\">23738544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(27):734-737. doi: 10.15585/mmwr.mm6627e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/28704351/pubmed\" target=\"_blank\" id=\"28704351\">28704351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soliris (eculizumab) [prescribing information]. New Haven, CT: Alexion Pharmaceuticals Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soliris (eculizumab) [product monograph]. Zurich, Switzerland: Alexion Pharma GmbH; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor CM, Machin S, Wigmore SJ, et al, &ldquo;Clinical Practice Guidelines for the Management of Atypical Haemolytic Uraemic Syndrome in the United Kingdom,&rdquo; <i>Br J Haematol</i>, 2010, 148(1):37-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/eculizumab-drug-information/abstract-text/19821824/pubmed\" target=\"_blank\" id=\"19821824\">19821824</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8836 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708724\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F4426547\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10205364\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F4426550\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F4426649\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13259673\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F4426650\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F4426651\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F4426652\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F4426659\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F4426548\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874616\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F4426653\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F4426551\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45748323\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F4426631\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F4426627\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F4426628\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299250\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220068\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4426623\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F4426626\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F4426656\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F4426642\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F4426644\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324130\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038892\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8836|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=eculizumab-patient-drug-information\" class=\"drug drug_patient\">Eculizumab: Patient drug information</a></li><li><a href=\"topic.htm?path=eculizumab-pediatric-drug-information\" class=\"drug drug_pediatric\">Eculizumab: Pediatric drug information</a></li></ul></div></div>","javascript":null}